ESMO publishes guidance on use of AI‐based biomarkers in oncology

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, an ESMO guideline will address the fact that despite increasing interest in and regulatory approval of AI‐based tools in oncology, there has been no shared definition or validation standard for these systems. In addition, T‐DXd shows benefit over T‐DM1 in patients with early breast cancer, and adding carboplatin to adjuvant chemotherapy improved survival in early‐stage triple‐negative breast cancer.